Duvic M et al. Efficacy of denileukin diftitox retreatment in patients with cutaneous T-cell lymphoma who relapsed after initial response. Proc ASH 2010;Abstract 2863.

Horwitz SM et al. Identification of an active well tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL): Final results of a multicenter dose finding study. Proc ASH 2010;Abstract 2800.

Dr Foss is Professor of Medicine and Director of Clinical Investigation of Hematological Malignancies at the Yale Cancer Center Section of Medical Oncology/Hematology in New Haven, Connecticut.

Dr Horwitz is Assistant Attending in the Division of Hematologic Oncology’s Lymphoma Service at Memorial Sloan-Kettering Cancer Center in New York, New York.